Products - Cervical cancer | Topic | NICE

Showing 5 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter
Status: PublishedRemove ‘Status: Published’ filter

Cemiplimab for treating recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy (TA1174)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 July 2026
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment (TA1164)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 June 2026
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer (TA939)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 December 2023
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2009
Guidance on the use of liquid-based cytology for cervical screening (TA69)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 October 2003